News & Updates
Filter by Specialty:
VELO supports liquid biopsy-guided anti-EGFR rechallenge therapy in mCRC
In the phase II VELO trial, third-line (3L) treatment with the anti-EGFR* monoclonal antibody (mAb) panitumumab and standard of care (SoC) improved progression-free survival (PFS) in patients with refractory RAS wild-type metastatic colorectal cancer (WT mCRC).
VELO supports liquid biopsy-guided anti-EGFR rechallenge therapy in mCRC
12 Sep 2023
SMAD7 overexpression boosts EGFR-CAR-T function against NSCLC
Epidermal growth factor receptor (EGFR)-mothers against decapentaplegic homologue 7 (SMAD7)-Chimeric antigen receptor (CAR) T-cell therapy against nonsmall-cell lung cancer (NSCLC) is on a par with EGFR-dominant‒negative transforming growth factor (TGFbeta) receptor 2 (DNR)-CAR-T in terms of efficacy and resistance to negative TGFβ regulation, a study has shown.
SMAD7 overexpression boosts EGFR-CAR-T function against NSCLC
10 Sep 2023
Better assessment of energy requirements needed in CRC patients
Using 30 kcal/kg to predict energy requirements overestimates total energy expenditure (TEE) by 1.44 times in patients with colorectal cancer (CRC) in a controlled sedentary environment, as shown in a study. In addition, TEE is outside of the predicted requirement range for most.
